Donate
Promised Price Cuts Not Cutting It: There is No $35 Price Cap on Insulin

Promised Price Cuts Not Cutting It: There is No $35 Price Cap on Insulin

Facebook Google LinkedIn Twitter

Newspaper headlines across America in January of 2024 have been blaring some incredible news: $35 insulin!

The #insulin4all movement has had some major victories lately. For example, Medicare beneficiaries can access $35 copays for some insulins. The list price of insulin went down for nine insulins. Over half of the states in the USA have passed some form of insulin copay cap. These victories were hard fought by #insulin4all advocates over the past decade.

But we’re not celebrating the much heralded $35 insulin cap for all. Because it’s not true.

Unfortunately, insulin remains too expensive for too many people living with diabetes across the United States. Put simply: the touted “$35 insulin caps” by headlines just don’t exist. What the media and politicians are talking about are copay cards, insulin savings cards, and patient assistance programs – manufacturer-sponsored cost-sharing programs. These programs are not new. They have been around for years. And yet, one in four patients with diabetes still rations insulin due to cost.

Manufacturer-sponsored cost-sharing programs are not an answer to the insulin price crisis. They have a lot of different issues that make them hard for patients to access. These programs vary wildly, and change all the time, putting patients at risk when they change terms or cancel their offerings altogether.

The programs can be onerous and challenging for prescribers and pharmacists to use. Sometimes extensive paperwork requires the time and attention of health professionals, or computer systems at the pharmacy counter cannot run the coupons. Additionally, manufacturers can collect any information they want about patients who use them, making them available for direct-to-patient drug advertising (which, yes, is still legal in the USA). LillyCares, NovoCare, and Sanofi Patient Connection applications all have the applicant sign away their right to privacy.

To make matters worse, reliance on coupons, savings cards, and patient assistance programs can circumvent efforts to make more cost-effective generic or biosimilar drugs more available. This is in art because these programs often transition patients to name brand, newer, and more expensive and still patented insulins, a practice called “product-hopping". Coupons have been found to increase the purchase of name-brand drugs over generics by over 60% and increase sales to newer, name-brand drugs.

Rather than celebrating “solutions” that still keep power in the hands of Big Pharma, we need legislation that ensures prices are cut and stay low, and that there is truly equitable insulin access for all.

So many of us are scrambling to afford insulin as new deductibles reset and reeling at the news of Levemir’s discontinuation. Celebrating $35 insulins for all patients is irresponsible and dangerous while so many continue to pay full price without insurance.

Are you struggling with the costs of insulin and needs support? We have compiled a list of resources that we hope might support you.

For more information, see our Policy Playbook.

Related posts:

The movement for public insulin production continues to grow in the United States

The movement for public insulin production continues to grow in the United States

This blog post was first published in Bridge Michigan on May 28, 2024 by Quinn Nichols, Nicole Koonce, and Allison Hardt under the title: Michigan has a chance to learn from California’s public pharma initiative. Read more

T1International Invited to White House Event

T1International Invited to White House Event

T1International advocates, Jesús Morales Sánchez (Communities of Color Working Group Co-Leader), Kristen Whitney Daniels (Federal Working Group Co-Leader), Lib Gatti (USA Advocacy Manager), and Shaina Kasper (Policy and Advocacy Director), were honored to be invited to a recent event at the White House focused on lowering healthcare costs. The event celebrated the success of the access to medicines movement in achieving a $35 monthly cap on out-of-pocket costs for insulin for Medicare Part D beneficiaries, allowing Medicare to negotiate drug prices directly with pharmaceutical companies, and more. Read more

Global Day of Action for #insulin4all demands insulin equity NOW

Global Day of Action for #insulin4all demands insulin equity NOW

On March 16, 2024, hundreds of #insulin4all advocates participated in over a dozen events across the globe calling for insulin access and affordability as part of the Global Day of Action for #insulin4all, sharing their stories on the critical need for insulin equity now. Read more

Levemir Discontinuation Impacts Patients

Levemir Discontinuation Impacts Patients

Only eight days of National Diabetes Awareness Month had passed this November when pharmaceutical company Novo Nordisk announced it would be pulling Levemir, a long-acting insulin that millions of insulin-dependent diabetic patients depend on, from the U.S. market. Read more

Eli Lilly: We Can't Find the $25 Insulin

Eli Lilly: We Can't Find the $25 Insulin

On March 1, Eli Lilly announced it would reduce the list prices of some of its insulins, including the generic Lispro, the same product as the name-brand Humalog. At a recent congressional hearing with the CEOs of insulin manufacturers and pharmacy benefit managers, David Ricks, Eli Lilly’s CEO, again celebrated that $25 insulin lispro was available to patients as of May 1. People with diabetes have worked tirelessly to reduce insulin costs for decades. So why aren’t we universally celebrating this announcement of lower prices? Because it is now the end of May, and I - and many others in my community - still haven’t been able to get the promised $25 insulin.
Read more

Eli Lilly and Novo Nordisk: More Empty Promises

Eli Lilly and Novo Nordisk: More Empty Promises

Outrage at soaring insulin prices in the USA has been increasing. More patients and families are speaking out against unaffordable costs for life-saving medication than ever before. In response, two of the 'Big Three' insulin makers (who control over 90% of the insulin market) have recently made moves to combat this anger. Read more